Working... Menu

GORE® Embolic Filter in Carotid Stenting for High Risk Surgical Subjects (EMBOLDEN) (EMBOLDEN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00766493
Recruitment Status : Completed
First Posted : October 6, 2008
Results First Posted : August 7, 2012
Last Update Posted : September 29, 2016
Information provided by (Responsible Party):
W.L.Gore & Associates

Brief Summary:
Compare the 30-day safety and efficacy of the GORE® Embolic Filter used in conjunction with FDA-approved carotid stents to a performance goal obtained from carotid stent studies utilizing distal embolic protection.

Condition or disease Intervention/treatment Phase
Carotid Artery Stenosis Device: GORE® Embolic Filter Phase 3

Detailed Description:
Continuous advances in angioplasty techniques and the development of low-profile, flexible, tapered nitinol stents designed specifically for carotid applications have made CAS a viable alternative to CEA. Advances in embolic protection technology will assist in moving CAS forward as a universally accepted procedure. While the GORE® Embolic Filter is similar in many ways to other currently available filters, it has been designed to provide optimal vessel wall apposition. Bench tests suggest that the wall apposition may provide improved filter efficiency, thereby minimizing embolization of particles downstream and potentially decreasing adverse clinical effects. In addition, preclinical testing suggests that the GORE® Embolic Filter has improved deliverability, including torque ability and lesion cross that may improve the ability of the system to access and treat tight lesions in tortuous anatomy. Thus, the purpose of this multi-center clinical study is to assess the safety and effectiveness of the GORE® Embolic Filter when used to provide cerebral embolic protection during carotid artery angioplasty and stenting.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 250 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: GORE® Embolic Filter in Carotid Stenting for High Risk Surgical Subjects (GORE EMBOLDEN)
Study Start Date : January 2009
Actual Primary Completion Date : July 2010
Actual Study Completion Date : July 2010

Arm Intervention/treatment
Experimental: GORE® Embolic Filter
Subjects treated with the GORE® Embolic Filter and an FDA-approved carotid stent.
Device: GORE® Embolic Filter
Embolic protection during carotid stenting

Primary Outcome Measures :
  1. Composite Major Adverse Event (MAE) Rate of Death, Myocardial Infarction, and Stroke at 30 Days Postprocedure [ Time Frame: 30 days ]

Secondary Outcome Measures :
  1. Device Success [ Time Frame: Post Procedure ]
    Device Success defined as the number of participants with Technical Success using the GORE Embolic Protection System (i.e., the GORE Embolic Filter device was delivered, placed, and retrieved as outlined in the Instructions for Use).

  2. Clinical Success [ Time Frame: 30 days ]
    Clinical Success defined as GORE Embolic Filter and carotid stent success in the absence of death, emergency endarterectomy, repeat PTA / thrombolysis of the target vessel, and stroke or MI as determined by the Clinical Events Committee. Clinical success will be evaluated from procedure through 24-48 hours postprocedure.

  3. Access Site Complications [ Time Frame: 30 days ]
    Access Site Complications defined as the presence of a large hematoma (>5cm or requiring treatment or prolonged hospitalization), fistula or pseudoaneurysm formation, retroperitoneal bleeding or the need for surgical repair postprocedure.

  4. Neurologic Events [ Time Frame: 30 days ]
    Neurological Events at 30 days post-procedure, including transient ischemic attacks (TIAs).

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Subject is either:

    • Symptomatic (amaurosis fugax in the hemisphere supplied by the target vessel, TIA or non-disabling stroke within 6 months of the procedure) with carotid stenosis ≥50% as diagnosed by angiography using NASCET methodology, OR
    • Asymptomatic with carotid stenosis ≥80% as diagnosed by angiography using NASCET methodology
  2. Target lesion is located in one of the following:

    • ICA
    • bifurcation
    • CCA proximal to the bifurcation
  3. At Anatomic risk for adverse events from CEA (e.g., restenosis after a prior CEA) or at Co-morbid risk for adverse events from CEA (e.g., unstable angina with ECG changes)

Exclusion Criteria:

  • Recent surgical procedure within 30 days before or after the stent procedure
  • Uncontrolled sensitivity to contrast media
  • Renal Insufficiency
  • Recent evolving, acute stroke within 21 days of study evaluation
  • Myocardial infarction within 72 hours prior to stent procedure
  • History of a prior major ipsilateral stroke with residual neurological deficits likely to confound the neurological assessments (e.g., NIHSS)
  • Neurological deficits not due to stroke likely to confound the neurological assessments (e.g., NIHSS)

Angiographic Exclusion Criteria:

  • Isolated ipsilateral hemisphere leading to subject intolerance to reverse flow
  • Total occlusion of the ipsilateral carotid artery
  • Pre-existing stent in the ipsilateral carotid artery OR the contralateral carotid artery that extends into the aortic arch
  • Presence of a filling defect, thrombus, occlusion or "string sign" in the target vessel
  • Severe lesion calcification restricting stent deployment
  • Carotid stenosis located distal to target stenosis that is more severe than target stenosis
  • >50% stenosis of the CCA proximal to target vessel
  • Known mobile plaque in the aortic arch

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00766493

Sponsors and Collaborators
W.L.Gore & Associates
Layout table for investigator information
Principal Investigator: William A. Gray, MD Columbia University

Layout table for additonal information
Responsible Party: W.L.Gore & Associates Identifier: NCT00766493     History of Changes
Other Study ID Numbers: GEF-06-08
First Posted: October 6, 2008    Key Record Dates
Results First Posted: August 7, 2012
Last Update Posted: September 29, 2016
Last Verified: August 2016

Keywords provided by W.L.Gore & Associates:
carotid artery stenosis
embolic protection device
distal embolic filter
minimizing risks of carotid artery stenting

Additional relevant MeSH terms:
Layout table for MeSH terms
Carotid Stenosis
Carotid Artery Diseases
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases